Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q00403
UPID:
TF2B_HUMAN
Alternative names:
General transcription factor TFIIB; S300-II
Alternative UPACC:
Q00403; A8K1A7; Q5JS30
Background:
Transcription initiation factor IIB, also known as General transcription factor TFIIB or S300-II, is pivotal in transcription initiation by RNA polymerase II. It facilitates pre-initiation complex formation and Pol II recruitment at promoter DNA, playing a crucial role in bridging TBP and the Pol II-TFIIF complex. This protein binds to distinct DNA core promoter consensus sequence elements, modulating transcription start site selection.
Therapeutic significance:
Understanding the role of Transcription initiation factor IIB could open doors to potential therapeutic strategies.